<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105750</url>
  </required_header>
  <id_info>
    <org_study_id>016</org_study_id>
    <nct_id>NCT05105750</nct_id>
  </id_info>
  <brief_title>A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis</brief_title>
  <official_title>A Comparative Study on Antiplatelet Efficacy of Indobufen and Aspirin in Patients With Coronary Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In addition, studies have found that indobufen can inhibit coagulation function in rats.&#xD;
      Compared with aspirin, the duration of antiplatelet efficacy of indobufen was shorter, and&#xD;
      the platelet function recovered completely 24 hours after drug withdrawal. However, there are&#xD;
      few studies on the antiplatelet efficacy of indobufen. The investigators' previous study&#xD;
      found that the inhibitory effect of indobufen 100 mg Bid on COX system in atherosclerosis or&#xD;
      healthy volunteers was equivalent to that of aspirin 100 mg QD, but the inhibitory effect on&#xD;
      platelet COX-1 channel was significantly weaker than that of aspirin 100 mg QD. In view of&#xD;
      this, this study intends to investigate the antiplatelet effect of indobufen 200 mg Bid in&#xD;
      patients with coronary atherosclerosis by comparing it with conventional-dose aspirin 100 mg&#xD;
      QD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">March 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MPA</measure>
    <time_frame>Within 24 hours after one month of medication</time_frame>
    <description>Maximum platelet aggregation induced by arachidonic acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TXB2</measure>
    <time_frame>Within 1 month after one month of medication</time_frame>
    <description>Plasma thromboxaneB2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>11-dh-TXB2</measure>
    <time_frame>Within 1 month after one month of medication</time_frame>
    <description>Urine 11-dehydro thromboxaneB2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Within 1 month after the first medication</time_frame>
    <description>Monitor the bleeding events of subjects during the trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>aspirin 100 mg/d therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>indobufen 200 mg bid therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 100 mg/d</intervention_name>
    <description>100mg aspirin for at least 3 days followed by aspirin 100 mg/d</description>
    <arm_group_label>aspirin 100 mg/d therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indobufen 200 mg bid</intervention_name>
    <description>100mg aspirin for at least 3 days followed by indobufen 200 mg bid</description>
    <arm_group_label>indobufen 200 mg bid therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of coronary atherosclerosis without indications for stent&#xD;
             implantation.&#xD;
&#xD;
          2. Age ≥ 18 years, ≤ 65 years&#xD;
&#xD;
          3. Sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of asthma or allergic constitution or known allergy to indobufen or aspirin.&#xD;
&#xD;
          2. High risk of bleeding (low hemoglobin 10g / L, history of peptic ulcer disease, fecal&#xD;
             occult blood positive or known active bleeding, history of cerebral hemorrhage within&#xD;
             6 months, history of fundus hemorrhage, etc).&#xD;
&#xD;
          3. Creatinine was 1.2 times higher than the upper limit of normal value and ALT was 1.2&#xD;
             times higher than the normal value.&#xD;
&#xD;
          4. History of smoking and alcoholism.&#xD;
&#xD;
          5. History of diabetes.&#xD;
&#xD;
          6. Pregnancy and lactation women.&#xD;
&#xD;
          7. Nonsteroidal anti-inflammatory or other antithrombotic drugs other than indobufen are&#xD;
             required.&#xD;
&#xD;
          8. Any other reason may affect the results of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Chunjian, Ph.D</last_name>
    <phone>86-25-83718836</phone>
    <email>lijay@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye Zekang</last_name>
    <phone>17816872076</phone>
    <email>yezekang@njmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Dr., MD, Ph.D, Director of CCU Ward</investigator_title>
  </responsible_party>
  <keyword>Light Transmittance Aggregometry</keyword>
  <keyword>Indobufen</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Plasma Thromboxane</keyword>
  <keyword>Urine 11-dehydro thromboxane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Indobufen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

